India's Sun Pharma recalls epilepsy treatment levetiracetam batch over failed dissolution tests

SINGAPORE--Sun Pharma issued a recall of 3,363 bottles of its levetiracetam extended-release drug for treating epilepsy in the United States after the tablets failed dissolution tests. The Class II recall announced by the U.S. FDA said Sun's recall was voluntary and involved tests at the six-month period. Sun markets the drug in India as Levipil in lower strengths as an anticonvulsant for epilepsy patients and as Keppra in the United States where it is produced by UCB Pharmaceuticals. Report